Furthermore, the recently finished Volume Substitution and Insulin Therapy in Severe Sepsis trial, a randomised multicentre trial designed to assess the efficacy and safety of intensive insulin therapy in patients with severe sepsis and septic shock, was stopped early for safety reasons [16]. The gene discussed is INS; the disease is Shock.